Personalis and Tempus Collaborate to Advance Cancer Testing
Personalis and Tempus Labs announced a collaboration to co-commercialize a whole genome-based liquid biopsy LDT for MRD and cancer detection.
Read MorePosted by Andy Lundin | Dec 4, 2023 | Cancer, Company News |
Personalis and Tempus Labs announced a collaboration to co-commercialize a whole genome-based liquid biopsy LDT for MRD and cancer detection.
Read MorePosted by Andy Lundin | Nov 1, 2023 | Cancer |
Researchers developed a highly sensitive blood test that detects a key protein produced by cancer cells, showing promise for early detection.
Read MorePosted by Andy Lundin | Oct 24, 2023 | Cancer |
Researchers detected cancer earlier in individuals with Li-Fraumeni syndrome, an inherited condition with a high risk of developing cancer.
Read MorePosted by Andy Lundin | Oct 23, 2023 | Cancer, Molecular Diagnostics |
VolitionRx detailed a new liquid biopsy cancer-detection method at the annual congress of the European Society for Medical Oncology.
Read MorePosted by Andy Lundin | Oct 4, 2023 | Cancer, Company News |
EValuate Diagnostics aims to make tests that detect cancer early, and will market a system for the capture of extracellular vesicles.
Read More